New Antibiotic, Manikomycin, Acts on Novel Ribosomal Target

▤ Summary

Researchers at McMaster University identified manikomycin, a new antibiotic from Streptomyces rimosus, and showed it works against multiple bacteria including multidrug-resistant Enterobacteriaceae. The compound is notable because it targets the E-site of the bacterial ribosome, a mechanism not seen in currently prescribed antibiotics. The team says this opens the door to a new class of treatments and could help overcome existing resistance patterns. The researchers are now advancing the molecule toward clinical development and optimizing derivatives for better performance.

▦ Linked Companies